B-cell Pathophysiology

How it works

Background

Highlighted claims

• The immune origin of idiopathic nephrotic syndrome was first proposed by Shaloub in 1974, with T-cells as the dominant hypothesis for decades. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
• The therapeutic effectiveness of rituximab shifted understanding of nephrotic syndrome pathophysiology toward a key role for B-cells. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
• The identification of anti-nephrin autoantibodies, immunoglobulin immunoadsorption efficacy, and B-cell dysregulation collectively support a humoral autoimmune aetiology for nephrotic syndrome. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
• Memory B-cells (CD19+/CD27+) have been identified as having a specific contributory role in idiopathic nephrotic syndrome. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial